000283111 001__ 283111
000283111 005__ 20260102125120.0
000283111 0247_ $$2doi$$a10.1002/alz70857_098147
000283111 0247_ $$2ISSN$$a1552-5260
000283111 0247_ $$2ISSN$$a1552-5279
000283111 037__ $$aDZNE-2026-00007
000283111 082__ $$a610
000283111 1001_ $$0P:(DE-2719)9003021$$aGerards, Michelle$$b0$$udzne
000283111 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283111 245__ $$aThe Role of Risk Perception and Psychosocial Factors in Attitudes and Views on Preclinical Dementia Risk Estimation – The PreTAD‐Study
000283111 260__ $$c2025
000283111 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767344301_32515
000283111 3367_ $$033$$2EndNote$$aConference Paper
000283111 3367_ $$2BibTeX$$aINPROCEEDINGS
000283111 3367_ $$2DRIVER$$aconferenceObject
000283111 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283111 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283111 3367_ $$2ORCID$$aOTHER
000283111 520__ $$aBackground:Advances in disease-modifying treatments and blood-based biomarkers for Alzheimer's disease (AD) have increased the importance of early diagnosis and dementia risk estimation before symptom onset. Autonomous decisions about AD risk estimation are complex and should align with individual needs and preferences. The PreTAD study (Predictive Turn in Alzheimer's Disease: Ethical, Clinical, Linguistic, and Legal Aspects) evaluates and compares attitudes on dementia risk estimation among first-degree relatives of individuals with dementia and patients with subjective cognitive decline to improve counseling for preclinical predictive AD diagnostics in the future.Method:PreTAD assesses risk perception, attitudes and views on AD dementia risk estimation, along with influencing psychosocial factors (living situation, loneliness, resilience, anxiety, and depression). The risk perception survey assessed participants’ opinions on two aspects: (1) what percentage they consider to represent a high general risk of developing AD dementia (perceived high general dementia risk), and (2) their perceived personal risk of developing AD dementia within 10 years (personal dementia risk).Result:Results from 390 participants in Germany, Switzerland, and Spain are presented. The perceived high general dementia risk assessed by participants ranged from >0%-100%. Around 30% perceived their personal dementia risk as 0–10%, while 70% rated their personal dementia risk as higher than 10%. Higher estimated personal dementia risk was associated with a greater estimated impact of biomarker-based early dementia risk estimation and clinical trial participation on the decision to estimate one's own dementia risk. Perceived high general dementia risk correlated with a higher influence of income, belief in the impact of lifestyle changes, and preference for high test accuracy over low invasiveness on the decision to estimate dementia risk. Higher perceived personal dementia risk correlated with lower resilience and higher anxiety.Conclusion:Risk perception is highly individual and may influence the process of AD dementia risk estimation. While psychosocial factors appear to have a limited impact on the decision to pursue dementia risk estimation in a hypothetical scenario, their impact in the subsequent process remains unclear. PreTAD findings highlight the need for personalized counseling that considers emotional and cognitive profiles to support informed decision-making in preclinical predictive AD diagnostics.
000283111 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283111 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283111 7001_ $$aHübner, Constanze$$b1
000283111 7001_ $$aBaumeister, Annika$$b2
000283111 7001_ $$aRibaldi, Federica$$b3
000283111 7001_ $$aCantero-Fortiz, Yahveth$$b4
000283111 7001_ $$aBraun, Julia$$b5
000283111 7001_ $$aBoada, Mercè$$b6
000283111 7001_ $$0P:(DE-2719)9001538$$aFrisoni, Giovanni B$$b7
000283111 7001_ $$aSchmitz-Luhn, Björn$$b8
000283111 7001_ $$aSchwegler, Carolin$$b9
000283111 7001_ $$aWoopen, Christiane$$b10
000283111 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b11$$udzne
000283111 7001_ $$aRostamzadeh, Ayda$$b12
000283111 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70857_098147$$gVol. 21, no. S3, p. e098147$$nS3$$pe098147$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283111 8564_ $$uhttps://pub.dzne.de/record/283111/files/DZNE-2026-00007.pdf$$yOpenAccess
000283111 8564_ $$uhttps://pub.dzne.de/record/283111/files/DZNE-2026-00007.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283111 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003021$$aExternal Institute$$b0$$kExtern
000283111 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000032$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000283111 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283111 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283111 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283111 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283111 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283111 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283111 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283111 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283111 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283111 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283111 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283111 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283111 9201_ $$0I:(DE-2719)1011102$$kAG Jessen$$lClinical Alzheimer’s Disease Research$$x0
000283111 980__ $$aabstract
000283111 980__ $$aVDB
000283111 980__ $$aUNRESTRICTED
000283111 980__ $$ajournal
000283111 980__ $$aI:(DE-2719)1011102
000283111 9801_ $$aFullTexts